NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-1 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES-TTS-1 is a transdermal clonidine system approved in 1984 for hypertension management. It works as a central alpha-2 adrenergic agonist, reducing sympathetic nervous system activity to lower blood pressure. The patch-based delivery system provides sustained, non-invasive dosing for chronic hypertension control.
LOE Approaching
LOE-approaching product with modest competitive pressure (30%), indicating a stabilization or contraction phase requiring defensive commercial strategies rather than expansion.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CATAPRES-TTS-1 offers stability in a mature product portfolio but limited career growth in innovation or market expansion. Roles emphasize operational efficiency, generic competition management, and customer retention rather than launch excitement or clinical innovation.
Product ManagerBrand Manager
Worked on CATAPRES-TTS-1 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.